Compare Lennar Corporation (LEN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs Merck & Co., Inc. — how do they compare? Lennar Corporation trades at $82.14 (market cap $19.92B), while Merck & Co., Inc. trades at $126.17 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 15.4× Lennar Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| LEN | MRK | |
|---|---|---|
Market Cap | $19.92B | $307.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $142.40 | $129.52 |
52-Week Low | $82.30 | $77.60 |
Enterprise Value | $23.80B | $350.66B |
Dividend Yield | 2.41% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lennar (LEN) trades at $82.53, down 1.62% today, with a bearish technical signal and recent earnings misses. The stock shows attractive valuation metrics with a P/E of 13.15 and P/S of 0.64, but faces margin compression as net income fell to $2.08 billion in 2025. Recent news highlights housing affordability challenges and the company's strategy to prioritize volume over price, with average selling prices at 2017 levels (The Motley Fool, June 24, 2026).
The outlook is mixed: analyst consensus is a Buy with a $84.78 target, but technicals and earnings trends suggest near-term pressure. Key risks include rising mortgage rates and housing demand softness, while potential catalysts include margin recovery efforts and supportive housing legislation. Execution on cost discipline and market share gains will be critical for upside.
Merck (MRK) trades at $124.30, down 2.51% over the past day, amid a generally bullish technical setup with moving averages signaling strength. The company reported solid earnings beats in recent quarters, including Q1 2026, with revenue reaching $65.01B in 2025 and net income of $18.25B. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives. Analyst sentiment remains strongly positive, with a consensus price target of $137.30 and 68% buy ratings.
The outlook for MRK is favorable, supported by robust profitability margins, strategic acquisitions, and strong institutional interest. Key risks include integration challenges from recent M&A, patent expirations, and regulatory pressures. The stock's current valuation at a P/E of 35.04 may limit near-term upside, but long-term growth drivers in pharmaceuticals provide a solid foundation for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
